Evidence map›Paper›PMID 31938212›Full record

ArticleInternational journal of clinical and experimental pathology2018

Suppressive role of microRNA-29 in hepatocellular carcinoma via targeting IGF2BP1.

Jianyi Yang, Xuejun Gong, Jing Yang, Linghua Ouyang, Rou Xiao, Xing You, Yanlan Ouyang

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. RNA m6A methylation regulators in liver cancer.Cancer cell international · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jianyi YangDepartment of General Surgery, Xiangya Hospital of Central South University Changsha, Hunan, PR China.
Xuejun GongDepartment of General Surgery, Xiangya Hospital of Central South University Changsha, Hunan, PR China.
Jing YangDepartment of General Surgery, Xiangya Hospital of Central South University Changsha, Hunan, PR China.
Linghua OuyangDepartment of General Surgery, Xiangya Hospital of Central South University Changsha, Hunan, PR China.
Rou XiaoDepartment of General Surgery, Xiangya Hospital of Central South University Changsha, Hunan, PR China.
Xing YouDepartment of General Surgery, Xiangya Hospital of Central South University Changsha, Hunan, PR China.
Yanlan OuyangDepartment of General Surgery, Xiangya Hospital of Central South University Changsha, Hunan, PR China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, ranking as the second leading cause of male cancer death worldwide. MicroRNA-29 (miR-29) has been demonstrated to act as a tumor suppressor in HCC. However, the regulatory mechanism of miR-29 underlying HCC growth and metastasis still remains obscure. In the present study, we showed that the expression of miR-29 was significantly reduced in HCC tissues and cell lines, and low miR-29 expression was associated with disease progression and shorter survival time of HCC patients. In vitro experiments showed that restoration of miR-29 expression caused a significant reduction in HCC cell proliferation, migration and invasion. Insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) was identified as a novel target gene of miR-29. The expression of IGF2BP1 was significantly increased in HCC tissues and cell lines. Moreover, IGF2BP1 was negatively regulated by miR-29 at the post-transcriptional levels in HCC cells. Furthermore, overexpression of IGF2BP1 attenuated the suppressive effects of miR-29 on the proliferation, migration, and invasion of HCC cells. According to these above findings, our study suggests that miR-29 may play a suppressive role in HCC growth and metastasis through directly targeting IGF2BP1. Therefore, miR-29 may be used as a potential candidate for the treatment of HCC.

Indexed as

Hepatocellular carcinomaIGF2BP1insulin like growth factor 2 mRNA binding protein 1microRNAtumor suppressor

Identifiers

PMID31938212
PMCPMC6958137
OpenAlexW3027374923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.